SHR-A1811 plus pyrotinib for advanced HER2+ breast cancer
Part of Cancer, Skin clinical trials.
This trial combines two targeted medications (SHR-A1811 and pyrotinib) for people with HER2-positive breast cancer that has spread or cannot be removed with surgery. It is for those whose cancer has stopped responding to previous HER2-targeted therapies or chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- Your breast cancer is HER2-positive and has spread to nearby or distant parts of the body.
- You have already tried HER2-targeted therapy and chemotherapy for advanced disease, or your cancer returned within a year of finishing similar treatment for early-stage cancer.
- You have at least one tumor that can be measured on scans.
- You are healthy enough to be up and active (ECOG 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether SHR-A1811 alone, or together with pyrotinib, given before surgery, can shrink HER2-positive breast cancer. It may help you respond better to treatment while making surgery easier.
This trial tests a new medicine called SHR-A1811 combined with other cancer treatments for advanced solid tumors that have HER2 protein or HER2 mutations. It may help people whose cancer has not responded to other treatments.
This trial tests a new antibody-drug conjugate, SHR-A1811, against the combination of pyrotinib and capecitabine in people with HER2-positive advanced breast cancer that no longer responds to trastuzumab (Herceptin). Researchers want to see if SHR-A1811 works better than the standard treatment.
This trial tests a new drug, SHR-1811, combined with carboplatin for advanced breast cancer that has HER2 expression (including low levels). It is for people who have already tried standard treatments and their cancer has spread or cannot be removed by surgery.
This trial tests whether taking pyrotinib continuously or intermittently can help people with HER2-positive advanced breast cancer that has spread. It is for those who have already received prior treatment for their advanced disease.
This study follows patients with advanced breast cancer that has a protein called HER2 to see how well pyrotinib (a targeted drug) works when used in routine clinical practice. You'd be tracked over time to understand how this treatment affects your cancer and quality of life.
Hear when a new Metastatic Breast Cancer With HER2 Positive trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.